{"groups":[{"description":"Taken once daily","id":"FG000","title":"AZD9291"},{"description":"Taken once daily","id":"FG001","title":"Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"4"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"21"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"42"},{"groupId":"FG001","numSubjects":"82"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}],"type":"Ongoing study at data cut-off"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}],"type":"Without specified reason"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"339"},{"groupId":"FG001","numSubjects":"343"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"337"},{"groupId":"FG001","numSubjects":"343"}],"type":"Received Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"261"},{"groupId":"FG001","numSubjects":"234"}],"comment":"(Study)","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"78"},{"groupId":"FG001","numSubjects":"109"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"During the 28 day screening period, participants were enrolled based on the presence of at least 1 of the 2 most frequent Epidermal growth factor receptor (EGFR) mutations in their tumor. At the time of enrolment, all participant were required to have central confirmation of EGFR mutation status per eligibility criteria (Exon 19 deletion or L858R mutation).","recruitmentDetails":"A total of 682 Patients were randomized to treatment at 245 Centers in 25 Countries."}